{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:23:42Z","timestamp":1774351422453,"version":"3.50.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associating 2 risk factors, total metabolic tumor volume (TMTV) &amp;gt;220 cm3 (determined by fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography) and performance status (PS) \u22652, identified as prognostic in 301 older patients in the REMARC trial (#NCT01122472), was validated in 2174 patients of all ages treated in 2 clinical trials, PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas; N\u00a0= 510) and GOYA (N\u00a0= 1315), and in real-world clinics (N\u00a0= 349) across Europe and the United States. Three risk categories, low (no factors), intermediate (1 risk factor), and high (2 risk factors), significantly discriminated outcome in most of the series. Patients with 2 risk factors had worse outcomes than patients with no risk factors in the PETAL, GOYA, and real-world series. Patients with intermediate risk also had significantly worse outcomes than patients with no risk factors. The TMTV\/Eastern Cooperative Oncology Group-PS combination outperformed the International Prognostic Index with a positive C-index for progression-free survival and overall survival in most series. The combination of high TMTV &amp;gt; 220 cm3 and ECOG-PS \u2265 2 is a simple clinical model to identify aggressive LBCL risk categories before treatment. This combination addresses the unmet need to better predict before treatment initiation for aggressive LBCL the patients likely to benefit the most or not at all from therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006923","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T17:03:42Z","timestamp":1661965422000},"page":"5995-6004","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[{"name":"1H\u00e9mato-oncologie, Universit\u00e9 de Paris, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France"}]},{"given":"Loic","family":"Chartier","sequence":"additional","affiliation":[{"name":"2Statistique, Lymphoma Academic Research Organisation, Pi\u00e9rre-Benite, France"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[{"name":"3Hematology, Universit\u00e4tsklinikum Essen, Essen, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"4Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5288","authenticated-orcid":false,"given":"Sally F.","family":"Barrington","sequence":"additional","affiliation":[{"name":"5King\u2019s College London & Guy\u2019s and St Thomas\u2019 PET Centre, School of Biomedical Engineering and Imaging Sciences, King\u2019s College London, London, United Kingdom"}]},{"given":"Jan M.","family":"Zaucha","sequence":"additional","affiliation":[{"name":"6Poland and Polish Lymphoma Research Group, Medical University of Gda\u0144sk, Gda\u0144sk, Poland"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[{"name":"7Medecine Nucl\u00e9aire, H\u00f4pital Saint-Louis, AP-HP, Paris, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-2450","authenticated-orcid":false,"given":"Maria","family":"Gomes Silva","sequence":"additional","affiliation":[{"name":"8Hematology, Instituto Portugu\u00eas de Oncologia de Lisboa (IPO Lisboa), Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-4754","authenticated-orcid":false,"given":"Ines","family":"Patrocinio-Carvalho","sequence":"additional","affiliation":[{"name":"9Nuclear Medecin, Instituto Portugu\u00eas de Oncologia de Lisboa (IPO Lisboa), Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-9910","authenticated-orcid":false,"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[{"name":"10Medecine Nucl\u00e9aire, Centre Henri Becquerel, Rouen, France"}]},{"given":"Pierre-Julien","family":"Viailly","sequence":"additional","affiliation":[{"name":"11Institut National de la Sante et de la Recherche Medicale U1245, Centre Henri Becquerel, Rouen, France"}]},{"given":"Herve","family":"Tilly","sequence":"additional","affiliation":[{"name":"11Institut National de la Sante et de la Recherche Medicale U1245, Centre Henri Becquerel, Rouen, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0771-7824","authenticated-orcid":false,"given":"Alina","family":"Berriolo-Riedinger","sequence":"additional","affiliation":[{"name":"12Medecine Nucl\u00e9aire, Centre Hospitalier Universitaire (CHU) le Bocage, Dijon, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Oliver","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"13H\u00e9matologie Centre, CHU le Bocage, Dijon, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-3873","authenticated-orcid":false,"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[{"name":"3Hematology, Universit\u00e4tsklinikum Essen, Essen, Germany"}]},{"given":"Hajira","family":"Ilyas","sequence":"additional","affiliation":[{"name":"5King\u2019s College London & Guy\u2019s and St Thomas\u2019 PET Centre, School of Biomedical Engineering and Imaging Sciences, King\u2019s College London, London, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-0328","authenticated-orcid":false,"given":"N. George","family":"Mikhaeel","sequence":"additional","affiliation":[{"name":"14Department of Clinical Oncology, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, London, United Kingdom"}]},{"given":"Joel","family":"Dunn","sequence":"additional","affiliation":[{"name":"5King\u2019s College London & Guy\u2019s and St Thomas\u2019 PET Centre, School of Biomedical Engineering and Imaging Sciences, King\u2019s College London, London, United Kingdom"}]},{"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[{"name":"15Medecine Nucl\u00e9aire, H\u00f4pital Cochin, AP-HP, Paris, France"}]},{"given":"Christine","family":"Schmitz","sequence":"additional","affiliation":[{"name":"3Hematology, Universit\u00e4tsklinikum Essen, Essen, Germany"}]},{"given":"Lale","family":"Kostakoglu","sequence":"additional","affiliation":[{"name":"16Radiology and Medical Imaging, University of Virginia, Charlottesville, VA"}]},{"given":"Joseph N.","family":"Paulson","sequence":"additional","affiliation":[{"name":"17Department of Biostatistics, Genentech Inc, South San Francisco, CA"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[{"name":"18F. Hoffmann-La Roche Ltd, Basel, Switzerland"}]},{"given":"Michael","family":"Meignan","sequence":"additional","affiliation":[{"name":"19Lymphoma Study Association-Image Platform, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}]}],"member":"234","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"20","key":"2023053018335226400_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023053018335226400_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"18","key":"2023053018335226400_bib3","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"6769","key":"2023053018335226400_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"5870","key":"2023053018335226400_bib5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"20","key":"2023053018335226400_bib6","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2023053018335226400_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2023053018335226400_bib8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023053018335226400_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"2023053018335226400_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"12","key":"2023053018335226400_bib11","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2023053018335226400_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2023053018335226400_bib13","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large\u00a0B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023053018335226400_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023053018335226400_bib15","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2023053018335226400_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2023053018335226400_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023053018335226400_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023053018335226400_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","article-title":"PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement","volume":"122","author":"Khan","year":"2013","journal-title":"Blood"},{"issue":"27","key":"2023053018335226400_bib20","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023053018335226400_bib21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023053018335226400_bib22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/annonc\/mdw137","article-title":"The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET\/CT: a Danish-Canadian study","volume":"27","author":"Alzahrani","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"2023053018335226400_bib23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2023053018335226400_bib24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"30","key":"2023053018335226400_bib25","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023053018335226400_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/jha2.421","article-title":"A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA","volume":"3","author":"Kostakoglu","year":"2022","journal-title":"eJHaem"},{"key":"2023053018335226400_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"issue":"15","key":"2023053018335226400_bib28","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2023053018335226400_bib29","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"key":"2023053018335226400_bib30","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood.V130.Suppl_1.824.824","article-title":"Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA study","volume":"130","author":"Kostakoglu","year":"2017","journal-title":"Blood"},{"issue":"31","key":"2023053018335226400_bib31","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023053018335226400_bib32","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"Duhrsen","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023053018335226400_bib33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"2023053018335226400_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2967\/jnumed.121.262464","article-title":"A guide to ComBat harmonization of imaging biomarkers in multicenter studies","volume":"63","author":"Orlhac","year":"2022","journal-title":"J\u00a0Nucl Med"},{"key":"2023053018335226400_bib35","author":"Kalbfleisch","year":"1980"},{"issue":"1","key":"2023053018335226400_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"issue":"9","key":"2023053018335226400_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023053018335226400_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","article-title":"Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"8","key":"2023053018335226400_bib39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"2023053018335226400_bib40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"issue":"28","key":"2023053018335226400_bib41","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023053018335226400_bib42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2020005002","article-title":"Predicting the future for DLBCL","volume":"135","author":"Cheson","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/5995\/2054142\/blooda_adv-2021-006923-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/5995\/2054142\/blooda_adv-2021-006923-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:34:29Z","timestamp":1685471669000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/23\/5995\/486458\/A-tumor-volume-and-performance-status-model-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":42,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006923","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}